
APPENDIX F

REFERENCES

REFERENCES TO STUDIES USED IN THE ECOLOGICAL ANALYSIS

- Aitken C, Brough R, Crofts N. *Injecting drug use and blood-borne viruses: a comparison of rural and urban Victoria, 1990-95*. Drug & Alcohol Review 1999; 18(1):47-52.
- Alfonso GR, Hurtado N, I, Espacio CA, Santos RG, Tomas DS. *Risk behaviours and seroprevalence to HIV, HBV and HCV in patients of the AIDS information and prevention center in Valencia, Spain*. Gaceta Sanitaria 1999; 13(1):16-21.
- Australian National Study of AIDS and Injecting Drug Use Study, (ANAIIDUS) (1991). *Neither a borrower nor a lender be: First report of the Australian National AIDS and injecting drug use study, 1989 data collection*. National Centre in HIV Social Research, University of New South Wales, Sydney.
- Azevedo-Neto RS, RC Bueno, F Mesquita, et al. *HIV Seroprevalence in IDUs from Santos: General Trends and Gender Analysis*. XI International Conference on AIDS, Vancouver, 1996; 7/7-14, Abstract Tu.C.2493.
- Baozhang T, Kaining Z, Jinxing K, Ruchang X, Ming L, Caixia Z, Li T. *Infection with human immunodeficiency virus and hepatitis viruses in Chinese drug addicts*. Epidemiology & Infection 1997; 119(3):343-347.
- Battjes RJ, Pickens RW, Brown LS (1995). *HIV infection and AIDS risk behaviours among injecting drug users entering Methadone Treatment: An update*. J Acq Immune Def Syndr & Human Retro, 10: 90-96.
- Bell J, Batey RG, Farrell GC, Crewe EB, Cunningham AL, Byth K. *Hepatitis C virus in intravenous drug users*. Medical Journal of Australia 1990; 153(5):274-276.
- Blacker P, Tindall B, Wodak A, Cooper D (1986). *Exposure of intravenous drug users to AIDS retrovirus, Sydney, 1985*. Aust & NZ J of Med, 16: 686-690.
- Bluthenthal RN, Kral AH, Lorvick JJ. *Risk behaviours among clients of tolerated and underground syringe exchange programs in the San Francisco Bay area*. 1996
- Bolumar F, Hernandez-Aguado I, Ferrer L, Ruiz I, Avino MJ, Rebagliato M. *Prevalence of antibodies to hepatitis C in a population of intravenous drug users in Valencia, Spain, 1990-1992*. International Journal of Epidemiology 1996; 25(1):204-209.
- Brajachand-Singh N, Ibotomba-Singh Y. *Absence of Serological Evidence of HIV in Manipur, a Border State of India*. Virus Information Exchange Newsletter. 1987; 4(3): 81.
- Broers B, Junet C, Bourquin M, Deglon JJ, Perrin L, Hirschel B. *Prevalence and incidence rate of HIV, hepatitis B and C among drug users on methadone maintenance treatment in Geneva between 1988 and 1995*. AIDS 1998; 12(15):2059-2066.
- Brunton C, Kemp R, Raynel P, Harte D, Baker M. *Cumulative incidence of hepatitis C seroconversion in a cohort of seronegative injecting drug users*. New Zealand Medical Journal 2000; 113(1106):98-101.
- Byrne A, Wodak A. *Census of patients receiving methadone treatment in a general practice*. Addiction Research 1996; 3(4):341-349.
- Byrne A (2000). *Nine year follow-up of 86 consecutive patients treated with methadone in general practice, Sydney, Australia*. Drug & Alcohol Rev, 19: 153-158.
- Cahn P, Perez H, Casiro A, et al. *Analysis of Spontaneous Attendance at an AIDS Consulting Centre in the City of Buenos Aires*. Medicina (Buenos Aires) 1988; 48: 125-131.

Cao K, Mizokami M, Orito E, Ding X, Ge XM, Huang GY, Ueda R. *TT virus infection among IVDUs in south western China*. Scandinavian Journal of Infectious Diseases 1999; 31(1):21-25.

Carruthers S, Loxley W. *Hepatitis C and young drug users: are they about to join the epidemic?* Australian Journal of Public Health 1995; 19(4):421-424

Carter H, Robinson G, Hanlon C, Hailwood C, Massarotto A. *Prevalence of hepatitis B and C infection in a methadone clinic population: implications for hepatitis B vaccination*. New Zealand Medical Journal 2001; 114(1136):324-326.

Celentano DD, Jittiwutikorn J, Hodge MJ, et al. *Epidemiology of HIV-1 Infection in Opiate Users in Northern Thailand*. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. 1997; 17(1): 73-78.

Chamot E, de Saussure P, Hirschel B, Deglon JJ, Perrin LH. *Incidence of hepatitis C, hepatitis B and HIV infections among drug users in a methadone-maintenance programme*. AIDS 1992; 6(4):430-431.

Chamot E, Hirschel B, Wintsh J, Robert CF, Gabriel V, Deglon JJ, Yerly S, Perrin L. *Loss of antibodies against hepatitis C virus in HIV-seropositive intravenous drug users*. AIDS 1990; 4(12):1275-1277.

Chang CJ, Ko YC, Liu HW. *Serum alanine aminotransferase levels in relation to hepatitis B and C virus infections among drug abusers in an area hyperendemic for hepatitis B*. Digestive Diseases & Sciences 2000; 45(10):1949-1952.

Chen DS, Kuo GC, Sung JL, Lai MY, Sheu JC, Chen PJ, Yang PM, Hsu HM, Chang MH, Chen CJ. *Hepatitis C virus infection in an area hyperendemic for hepatitis B and chronic liver disease: the Taiwan experience*. Journal of Infectious Diseases 1990; 162(4):817-822.

Chetwynd J, Brunton C, Blank M, Plumridge E, Baldwin D. *Hepatitis c seroprevalence amongst injecting drug users attending a methadone programme*. New Zealand Medical Journal 1995; 108(1007):364-366.

Choopanya K, Des Jarlais DC, Vanichseni S, et al. *Risk Factors for HIV Seroprevalence among IDUs in Bangkok, 1989 vs. 1993*. Tenth International Conference on AIDS, Yokohama, Japan. 1994; 8/7-12, Abstract P.C.0125.

Coppola RC, Masia G, di Martino ML, Carboni G, Muggianu E, Piro R, Manconi PE. *Sexual behaviour and multiple infections in drug abusers*. European Journal of Epidemiology 1996; 12(5):429-435.

Corona R, Prignano G, Mele A, Gentili G, Caprilli F, Franco E, Ferrigno L, Giglio A, Titti F, Bruno C. *Heterosexual and homosexual transmission of hepatitis C virus: relation with hepatitis B virus and human immunodeficiency virus type 1*. Epidemiology & Infection 1991; 107(3):667-672.

Crofts N, Aitken CK. *Incidence of blood borne virus infection and risk behaviours in a cohort of injecting drug users in Victoria, 1990-1995*. Medical Journal of Australia 1997; 167(1):17-20.

Crofts N. *Surveillance for HIV Infection and AIDS*. World Health Organization, Global Programme on AIDS, Kuala Lumpur, Malaysia, 7-27 October 1991, mission report. 1992.

Crofts N, Hopper JL, Bowden DS, Breschkin AM, Milner R, Locarnini SA. *Hepatitis C virus infection among a cohort of Victorian injecting drug users*. Medical Journal of Australia 1993; 159(4): 237-241

Crofts N, Hopper JL, Milner R, Breschkin AM, Bowden DS, Locarnini SA. *Blood-borne virus infections among Australian injecting drug users: implications for spread of HIV*. European Journal of Epidemiology 1994; 10(6):687-694.

Crofts N, Stewart T, Hearne P, Ping XY, Breshkin AM, Locarnini SA. *Spread of blood borne viruses among Australian prison entrants*. BMJ 1995; 310(6975):285-288.

Crofts N, Nigro L, Oman K, Stevenson E, Sherman J. *Methadone maintenance and hepatitis C virus infection among injecting drug users*. *Addiction* 1997; 92(8):999-1005.

Dan M, Rock M, Bar-Shany S. *Prevalence of Antibodies to Human Immunodeficiency Virus among Intravenous Drug Users in Israel - Association with Travel Aboard*. *International Journal of Epidemiology*. 1989; 18(1): 239-241.

Dan M. *HIV Infection and Intravenous Drug Abuse: World Perspective and Epidemiology in Israel*. *Israel Journal of Medical Sciences*. 1993; 29(10) (Suppl.): 11-14.

Darke S, Baker A, Dixon J, Wodak A, Heather N. *Drug use and HIV-risk taking among clients in methadone maintenance treatment*. *Drug & Alcohol Dependence*, 1992a 29: 263-268.

de Carvalho HB, Mesquita F, Massad E, Bueno RC, Lopes GT, Ruiz MA, Burattini MN. *HIV and infections of similar transmission patterns in a drug injectors community of Santos, Brazil*. *Journal of Acquired Immune Deficiency Syndromes* 1996; 12(1):84-92.

Delgado-Iribarren A, Calvo M, Perez A, del Alamo M, Cercenado S. *Intravenous drug users serologic control: what may be prevented?* [Spanish]. *Enfermedades Infecciosas y Microbiologia Clinica* 2000; 18(1):2-5.

Denham I & Hayes P. *Human immunodeficiency virus antibody testing at the Melbourne Sexually Transmitted Diseases Centre 1984-1989. Six years and 17,382 tests*. *Venerology*, 1990, 3: 4-11.

Denis B, Dedobbeleer M, Collet T, Petit J, Jamouille M, Hayani A, Brenard R. *High prevalence of hepatitis C virus infection in Belgian intravenous drug users and potential role of the "cotton-filter" in transmission: the GEMT Study*. *Acta Gastroenterologica Belgica* 2000; 63(2):147-153.

Des Jarlais DC., Subhachaturas W, Vanichseni S, et al. *Sexual Risk Behaviors of Injecting Drug Users in Bangkok, Thailand*. 12th World AIDS Conference, Geneva. 1998; 6/28-7/3, Abstract 23154.

Diamantis I, Bassetti S, Erb P, Ladewig D, Gyr K, Battegay M. *High prevalence and coinfection rate of hepatitis G and C infections in intravenous drug addicts*. *Journal of Hepatology* 1997; 26(4):794-797.

Diaz T, Des J, Vlahov D, Perlis TE, Edwards V, Friedman SR, Rockwell R, Hoover D, Williams IT, Monterroso ER. *Factors associated with prevalent hepatitis C: differences among young adult injection drug users in lower and upper Manhattan, New York City*. *American Journal of Public Health* 2001; 91(1):23-30.

Dimitrakopoulos A, Takou A, Haida A, Molangeli S, Gialeraki A, Kordossis T. *The prevalence of hepatitis B and C in HIV-positive Greek patients: relationship to survival of deceased AIDS patients*. *Journal of Infection* 2000; 40(2):127-131.

Donovan B, Finlayson RJ, Mutimer K. *HIV infection in sexually transmissible disease practice in Sydney: the effects of legislation, public education and changing clinical spectrum*. *Int J of STD & AIDS*, 1990, 1: 21-27.

Donahue JG, Nelson KE, Munoz A, Vlahov D, Rennie LL, Taylor EL, Saah AJ, Cohn S, Odaka NJ, Farzadegan H. *Antibody to hepatitis C virus among cardiac surgery patients, homosexual men, and intravenous drug users in Baltimore, Maryland*. *American Journal of Epidemiology* 1991; 134(10):1206-1211.

Dourado I, Andrade T, Montes JC, et al. *Human Retrovirus in a Brazilian City with a Population Predominantly of African Origin: Evidences for High Prevalence*. XI International Conference on AIDS, Vancouver. 1996; 7/7-14, Poster Pub.C.1132.

Duburcq A, Charpak Y, Blin P, Madec L. *Two years follow-up of heroin users treated by GPs with high dosage buprenorphine: the SPESUB study (pharmaco-epidemiological follow-up of high dosage buprenorphine in general practice)* [French]. *Revue d'Epidemiologie et de Sante Publique* 2000; 48(4):363-373.

Dwyer D, Bell J, Batey R, et al. *Low prevalence of human immunodeficiency virus infection in methadone program attenders and pregnant intravenous drug users in the western metropolitan region of Sydney.* Aus & NZ J of Med, 1989, 19: 407-408.

Edeh J, Spalding P. *Screening for HIV, HBV and HCV markers among drug users in treatment in rural south-east England.* Journal of Public Health Medicine 2000; 22(4):531-539.

Eicher AD, Crofts N, Benjamin S, Deutschmann P, Rodger AJ. *A certain fate: spread of HIV among young injecting drug users in Manipur, North-East India.* AIDS Care 2000; 12(4):497-504.

European Centre for the Epidemiological Monitoring of AIDS (ECDMA). *HIV/AIDS surveillance in Europe. Mid Year report 2001.* 2001 No. 65.

European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) *Annual report on the state of the drugs problem in the European Union, 2000.* Office for Official Publications of the European Communities, Luxembourg.

Fairley CK, Leslie DE, Nicholson S, Gust ID. *Epidemiology and hepatitis C virus in Victoria.* Medical Journal of Australia 1990; 153(5):271-273.

Ferreira A, Arevalo E, Fernandes NEL, et al. *HIV Infection among Users and Non Users of Injected Drugs.* VIII International Conference on AIDS, Amsterdam, 1992; 7/19-24, Abstract PuC 8072.

Fingerhood MI, Jasinski DR, Sullivan JT. *Prevalence of Hepatitis C in a chemically dependent population.* Archives of Internal Medicine 1993; 153(17):2025-2030.

Fisher DG, Fenaughty AM, Paschane AA, Paschane DM, Cagle HH, Orr SM. *Hepatitis c virus infection among Alaskan drug users.* American Journal of Public Health 1997; 87(10):1722-1724.

Francisci D, Baldelli F, Papili R, Stagni G, Pauluzzi S. *Prevalence of HBV, HDV and HCV hepatitis markers in HIV-positive patients.* European Journal of Epidemiology 1995; 11(2):123-126.

Friedman SR, Des Jarlais DC. *HIV among drug injectors: the epidemic and the response.* AIDS Care 1991,3 (3) 239-250

Friedman SR, Jose B, Deren S, Des Jarlais DC, *Neagigus for the National AIDS Research Consortium. Risk factors for human immunodeficiency virus seroconversion among out-of-treatment drug injectors in high and low seroprevalence cities.* 1995, 142,(8):864-874.

Frischer M, Bloor M, Green S, Goldberg D, Covell R, McKeganey, Taylor. *Reduction in needle sharing among community wide samples of injecting drug users.* International Journal of STD & AIDS 1992; 3: 288-290.

Freeman AJ, Zekry A, Whybin LR, Harvey CE, van Beek IA, de Kantzow SL, Rawlinson WD, Boughton CR, Robertson PW, Marinos G, Lloyd AR. *Hepatitis C prevalence among Australian injecting drug users in the 1970s and profiles of virus genotypes in the 1970s and 1990s.* Medical Journal of Australia 2000; 172(12):588-591.

Fuglsang T, Fouchard JR, Ege PP. *Prevalence of HIV and hepatitis B and C among drug addicts in the city of Copenhagen.* [Danish]. Ugeskrift for Laeger 2000; 162(27):3860-3864.

Galeazzi B, Tufano A, Barbierato E, Bortolotti F. *Hepatitis C virus infection in Italian intravenous drug users: epidemiological and clinical aspects.* Liver 1995; 15(4):209-212.

Garfein RS, Vlahov D, Galai N, Doherty MC, Nelson KE. *Viral infections in short-term injection drug users: the prevalence of hepatitis c hepatitis B, human immunodeficiency and human T-lymphotropic viruses.* American Journal of Puclic Health 1996; 86 (5): 655-661.

Garfein RS, Doherty MC, Monterroso ER, Thomas DL, Nelson KE, Vlahov D. *Prevalence and incidence of hepatitis C virus infection among young adult injection drug users*. Journal of Acquired Immune Deficiency Syndromes 1998; 18 Suppl 1:S11-S19.

Garner JJ, Gaughwin M, Dodding J, Wilson K. *Prevalence of hepatitis C infection in pregnant women in South Australia*. Medical Journal of Australia 1997; 167(9):470-472.

Gaughwin M, Dodding J, Ali R. *Hepatitis C and the history of injecting drug use in South Australia*. [letter; comment]. Medical Journal of Australia 1994; 161(4):286.

Gaughwin MD & Ali R. *HIV infection among injecting drug users in the South Australian methadone program*. Med J Aust, 1995, 162: 242-244.

Gianna MC, Chequer P, Castilho E, et al. *Profile of IVDU in an AIDS Reference Center, Sao Paulo, Brazil, 1988*. VI International Conference on AIDS, San Francisco, 1990; 6/20-24, Poster Th.C.713.

Girardi E, Zaccarelli M, Tossini G, Puro V, Narciso P, Visco G. *Hepatitis C virus infection in intravenous drug users: prevalence and risk factors*. Scandinavian Journal of Infectious Diseases 1990; 22(6):751-752.

Giuliani M, Caprilli F, Gentili G, Maini A, Lepri AC, Prignano G, Palamara G, Giglio A, Crescimbeni E, Rezza G. *Incidence and determinants of hepatitis c virus infection among individuals at risk of sexually transmitted diseases attending a human immunodeficiency virus type 1 testing program*. Sexually Transmitted Diseases 1997; 24(9):533-537.

Guimaraes ML, Bastos FI, Telles PR, Galvao-Casto B, Diaz RS, Bongertz V, Morgado MG. *Retrovirus infections in a sample of injecting drug users in Rio de Janeiro City, Brazil: prevalence of HIV-1 subtypes, and co-infection with HTLV-I/II*. Journal of Clinical Virology, 2001; 21: 143-151.

Goldberg D, Burns S, Taylor A, Cameron S, Hargreaves D, Hutchinson S. *Trends in HCV prevalence among injecting drug users in Glasgow and Edinburgh during the era of needle/syringe exchange*. Scandinavian Journal of Infectious Diseases 2001a; 33(6):457-461.

Goldberg D, Cameron S, McMenamin J. *Hepatitis C virus antibody prevalence among injecting drug users in Glasgow has fallen but remains high*. Communicable Disease & Public Health 1998; 1(2):95-97.

Goldberg D, Cameron S, Sharp G, Burns S, Scott G, Molyneaux P, Scoular A, Downie A, Taylor A. *Hepatitis C virus among genitourinary clinic attenders in Scotland: unlinked anonymous testing*. International Journal of STD & AIDS 2001b; 12(1):17-21.

Goldberg D, McIntyre PG, Smith R, Appleyard K, Dunlop J, Taylor A, Hutchinson S. *Hepatitis C virus among high and low risk pregnant women in Dundee: unlinked anonymous testing*. British Journal of Obstetrics & Gynaecology 2001c; 108(4):365-370.

Gore SM, Brett RP, Burns SM, Lewis SC. *Pilot study to estimate survivors to 1995 of 1983-1984 prevalent hepatitis c infections in lothian patients who tested positive or negative for hepatitis b surface antigen in 1983-1984*. Journal of Infection 1998; 37(2):159-165.

Guadagnino V, Zimatore G, Rocca A, Montesano F, Masciari R, Caroleo B, Izzi A, Morabito D, Naso E, Scicchitano R. *Anti-hepatitis C antibody prevalence among intravenous drug addicts in the Catanzaro area*. Archives of Virology - Supplementum 1992; 4:335-336.

Hagan H, Jarlais DC, Friedman SR, Purchase D, Alter MJ. *Reduced risk of hepatitis B and hepatitis C among injection drug users in the Tacoma syringe exchange program*. American Journal of Public Health 1995; 85(11):1531-1537.

-
- Hagan H, McGough JP, Thiede H, Weiss NS, Hopkins S, Alexander ER. *Syringe exchange and risk of infection with hepatitis B and C viruses*. American Journal of Epidemiology 1999; 149(3):203-213.
- Hagan H, Thiede H, Weiss NS, Hopkins SG, Duchin JS, Alexander ER. *Sharing of drug preparation equipment as a risk factor for hepatitis C*. American Journal of Public Health 2001; 91(1):42-46.
- Hahn RA, Onorato IM, Jones TS, Dougherty J. *Prevalence of HIV infection among intravenous drug users in the United States*. JAMA, 1989; Vol 261, No. 18: 2677-2684.
- Hahn JA, Page-Shafer K, Lum PJ, Ochoa K, Moss AR. *Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco*. Hepatology 2001; 34(1): 180-187.
- Hamers FF, Batter V, Downs AM, Alix J, Cazein F, Brunet JB. *The HIV epidemic associated with injecting drug use in Europe: geographic and time trends*. AIDS 1997, 11:1365-1374.
- Harsch HH, Pankiewicz J, Bloom AS, Rainey C, Cho JK, Sperry L, Stein EA. *Hepatitis C virus infection in cocaine users - a silent epidemic*. Community Mental Health Journal 2000; 36(3):225-233.
- Hart GJ, Woodward N, Johnson AM, Tighe J, Parry JV, Adler MW. *Prevalence of HIV, hepatitis B and associated risk behaviors in clients of a needle-exchange in central London*. AIDS 1992, 5:543-547.
- Health Canada. *Inventory of HIV incidence and prevalence studies in Canada*. April 2000.
- Htoon MT, Lwin HH, San KO, et al. *HIV/AIDS in Myanmar*. AIDS. 1994; 8(suppl. 2): S105-S109.
- Hwang LY, Ross MW, Zack C, Bull L, Rickman K, Holleman M. *Prevalence of sexually transmitted infections and associated risk factors among populations of drug abusers*. Clinical Infectious Diseases 2000; 31(4):920-926.
- Ichimura H, Kurimura O, Tamura I, Tsukue I, Tsuchie H, Kurimura T. *Prevalence of blood-borne viruses among intravenous drug users and alcoholics in Hiroshima, Japan*. International Journal of STD & AIDS 1995; 6(6):441-443.
- Inciardi JA, Surratt H, Telles P, et al. *Risks for HIV-1 Infection and Seropositivity Rates among Cocaine Users in Rio de Janeiro, Brazil*. XI International Conference on AIDS, Vancouver. 1996; 7/7-14, Session Th.C.425.
- Inciardi J, McBride D, Surratt H, et al. *Reducing HIV Risk among Cocaine Users in Rio de Janeiro, Brazil*. 12th World AIDS Conference, Geneva. 1998; 6/28 - 7/3, Poster 33407.
- Iqbal N. *Substance dependence - A hospital based survey*. Saudi Medical Journal 2000; 21(1):51-57.
- Iguchi MY, Bux DA, Lidz V, Kushner H, French JF, Platt JJ. *Interpreting HIV seroprevalence data from a street-based outreach program*. Journal of Acquired Immune Deficiency Syndromes 1994, 7:491-499.
- Ismail R. *HIV/AIDS in Malaysia*. AIDS. 1998; 12 (Suppl B):S33-S41.
- Jiang JJ, Dubois F, Driss F, Carnot F, Thepot V, Pol S, Berthelot P, Brechot C, Nalpas B. *Clinical impact of drug addiction in alcoholics*. Alcohol & Alcoholism 1995; 30(1):55-60.
- Johnson Z, O'Connor M, Pomeroy L, Johnson H, Barry J, Scully M, Fitzpatrick E. *Prevalence of HIV and associated risk behavior in attendees at a Dublin needle exchange*. Addiction 1994; 89 (5): 603-607.
- Kelen GD, Green GB, Purcell RH, Chan DW, Qaqish BF, Sivertson KT, Quinn TC. *Hepatitis B and hepatitis C in emergency department patients*. New England Journal of Medicine 1992; 326(21):1399-1404.

Kemp R, Miller J, Lungley S, Baker M. *Injecting behaviours and prevalence of hepatitis B, C and D markers in New Zealand injecting drug user populations*. New Zealand Medical Journal 1998; 111(1060):50-53.

Kitayaporn D, Vanichseni S, Mastro TD, et al. *Infection with HIV-1 Subtypes B and E in Injecting Drug Users Screened for Enrollment into a Prospective Cohort in Bangkok*. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. 1998; 19(3): 289-295.

Krook A, Albert J, Andersson S, Biberfeld G, Blomberg J, Eklund I, Engstrom A, Julander I, Kall K, Martin C, Stendahl P, Struve J, Sonnerborg A. *Prevalence and risk factors for HTLV-II infection in 913 injecting drug users in Stockholm, 1994*. Journal of Acquired Immune Deficiency Syndromes 1997; 15(5):381-386.

Lal S. *AIDS - A Priority Health Problem in India*. Swasth Hind. 1991; 35: 277.

Lamden KH, Kennedy N, Beeching NJ, Lowe D, Morrison CL, Mallinson H, Mutton KJ, Syed Q. *Hepatitis B and hepatitis C virus infections: Risk factors among drug users in Northwest England*. Journal of Infection 1998; 37(3):260-269.

Laskus T, Radkowski M, Werezynska T, Horban A, Lupa E, Cianciara J, Slusarczyk J. *Occurrence of antibodies against hepatitis C virus (HCV) among drug addicts*. [Polish]. Polskie Archiwum Medycyny Wewnetrznej 1992; 87(1):8-13.

Latt NC, Spencer JD, Beeby PJ, McCaughan GW, Saunders JB, Collins E, Cossart YE. *Hepatitis C in injecting drug-using women during and after pregnancy*. Journal of Gastroenterology & Hepatology 2000; 15(2):175-181.

Lee SD, Chan CY, Wang YJ, Wu JC, Lai KH, Tsai YT, Lo KJ. *Seroepidemiology of hepatitis C virus infection in Taiwan*. Hepatology 1991; 13(5):830-833.

Lestrem, MD, Fainboim H, Mendez N, et al. *HIV-1 Infection in Intravenous Drug Abusers with Clinical Manifestation of Hepatitis in the City of Buenos Aires*. In: AIDS Profile of an Epidemic, PAHO, Scientific Publication. 1989; 514: 51-60.

Li D, Zheng X, Zhang G. *Prevalence of HIV and HCV among injecting drug users (IDUs) in Yunnan, China*. [Chinese]. Chung-Hua Liu Hsing Ping Hsueh Tsa Chih Chinese Journal of Epidemiology 1994; 15(2):74-75.

Libonatti O, Lima E, Peruga A, et al. *Role of Drug Injection in the Spread of HIV in Argentina and Brazil*. International Journal of STD and AIDS. 1993; 4: 135-141.

Lima ES, Azevedo RCS, Manfrinatti MB, et al. *Risk Behaviors for HIV-1 Seroprevalence in a Sample of Injecting Drug Users (IDUS) and Crack Smokers (CSS) in Campinas, Brazil*. XI International Conference on AIDS, Vancouver. 1996; 7/7-14, Abstract Pub.C.1133.

Lindan CP, Lieu TX, Giang LT, et al. *Rising HIV Infection Rates in Ho Chi Minh City Herald Emerging AIDS Epidemic in Vietnam*. AIDS. 1997; 11(supp. 1): S5-S13.

Lohsomboon P, Young NL, Weniger BG, et al. *Nondetection of HTLV-III and HIV-2 in Thailand, 1991-1992*. Journal of Acquired Immune Deficiency Syndromes. 1994; 7(9): 992-994.

Lopez-Zetina J, Ford W, Weber M, Barna S, Woerhle T, Kerndt P, Monterroso E. *Predictors of syphilis seroreactivity and prevalence of HIV among street recruited injection drug users in Los Angeles County, 1994-6*. Sexually Transmitted Infections 2000; 76:462-469.

Lorvick J, Kral AH, Seal K, Gee L, Edlin BR. *Prevalence and duration of hepatitis C among injection drug users in San Francisco, Calif*. American Journal of Public Health 2001; 91(1):46-47.

Love A, Stanzeit B. *Hepatitis C virus infection in Iceland: a recently introduced blood-borne disease.* *Epidemiology & Infection* 1994; 113(3):529-536.

Loxley WM, Marsh AM, Hawks DV, Quigley AJ. *HIV risk behaviour among injecting drug users in Perth: the Australian National AIDS and injecting drug use study.* *Med J Aust*, 1992, 156: 687-692.

Loxley W, Ovenden C. *Friends and lovers: needle sharing in young people in Western Australia.* *AIDS Care* 1995; 7(3):337-351.

Lucidarme D, Foutrein P, Creusy C, Forzy G, Foutrein-Comes MC, Muysen A, Bailly D, Parquet PJ, Filoche B. *Prevalence of hepatitis C, B and D markers and histopathological aspects in a group of intravenous drug addicts.* [French]. *Gastroenterologie Clinique et Biologique* 1994; 18(11):964-968.

Luksamijarulkul P, Plucktaweesak S. *High hepatitis C seroprevalence in Thai intravenous drug abusers and qualitative risk analysis.* *Southeast Asian Journal of Tropical Medicine & Public Health* 1996; 27(4):654-658.

Maayan S, Shufman EN, Engelhard D, Shouval D. *Exposure to hepatitis B and C and to HTLV-1 and 2 among Israeli drug abusers in Jerusalem.* *Addiction* 1994; 89(7):869-874.

MacDonald M, Sullivan P, Locke A, Wodak A, Kaldor J. *HIV and HCV prevalence among trawler crew.* *Australian & New Zealand Journal of Public Health* 1998; 22(7):829-831.

Majid A, Holmes R, Desselberger U, Simmonds P, McKee TA. *Molecular epidemiology of hepatitis C virus infection amongst intravenous drug users in rural communities.* *Journal of Medical Virology* 1995; 46(1):48-51.

Mansson AS, Moestrup T, Nordenfelt E, Widell A. *Continued transmission of hepatitis B and C viruses, but no transmission of human immunodeficiency virus among intravenous drug users participating in a syringe/needle exchange program.* *Scandinavian Journal of Infectious Diseases* 2000; 32(3):253-258.

Marmor M, Des Jarlaid DC, Cohen H, Friedman SR, Beatrice ST, Dubin N, El-Sadr W, Mildvan D, Yancovitz S, Mathur U, Holzman R. *AIDS* 1987, 1:39-44.

McDonald AM, Whyte BM, Jacobs D, et al. *Voluntary HIV antibody testing among STD clinic patients: A pilot study.* *Med J Aust*, 1990, 153: 12-14.

McIntyre PG, Hill DA, Appleyard K, Taylor A, Hutchinson S, Goldberg DJ. *Prevalence of antibodies to hepatitis C virus, HIV and human T-cell leukaemia/lymphoma viruses in injecting drug users in Tayside, Scotland, 1993-7.* *Epidemiology & Infection* 2001; 126(1):97-101.

McKenna JG, Evans G, Lytle PH, Couper A. *Hepatitis C virus seroprevalence in patients attending a sexual health centre.* *New Zealand Medical Journal* 1994; 107(970):8-10.

Mesquita F, Moss AR, Reingold AL, et al. *Pilot Study of HIV Antibody Seroprevalence among IVDUs in the City of Santos Sao Paulo State, Brazil.* VII International Conference on AIDS, Florence, Italy, 1991; 6/16-21, Poster M.C.3008.

Metzger DS, Woody GE, McLellan T, O'Brien CP, Druley P, Navaline H, DePhilippis D, Stolley P, Abrutyn E. *Human immunodeficiency virus seroconversion among intravenous drug users in-and out-of-treatment: an 18 month prospective follow up.* *Journal of Acquired Immune Deficiency Syndromes* 1993; 6:1049-1056.

Ministry of Public Health Thailand. *National Sentinel Seroprevalence Survey.* 1991; (Oct. 28; Feb. 21), 1992 (June), 1993 (June & December), 1994 (June & December), 1996 (June), 1997 (June), 1998 (June), Unpublished tables.

Montoya ID, Atkinson JS. *Determinants of HIV seroprevalence rates among sites participating in a community-based study of drug users*. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1996; 13: 169-176.

Moriarty H, Kemp R, Robinson G. *Hepatitis services at an injecting drug user outreach clinic*. New Zealand Medical Journal 2001; 114(1128):105-106.

Morlet A, Darke S, Guinan J, Wolk J, Gold J). *Intravenous drug users who present to the Albion Street (AIDS) Centre for diagnosis and management of Human Immunodeficiency Virus infection*. Med J Aust. 1990, 152: 78-80.

Moss AR, Vranizan K, Gorter R, Bacchetti, Watters J, Osmond D. *HIV seroconversion in intravenous drug users in San Francisco, 1985 – 1990*. AIDS 1994, 8:223-231.

Muchnik GR, Picchio GR, Bouzas MB, et al. *Seroepidemiology of Human Immunodeficiency Virus in Low and High Risk Groups in Buenos Aires, Argentina*. AIDS-Forschung 1988; 3(2): 89-93.

National Centre in HIV Epidemiology and Clinical Research (NCHECR). *Annual Surveillance Report 2000: HIV/AIDS, hepatitis C and sexually transmissible infections in Australia*. 2001

Neuwald C, Pont J, Tomasits J, Bauer K. *Antibody prevalence for hepatitis C and other parenterally transmissible viral diseases in i.v. drug dependent patients*. [German]. Acta Medica Austriaca 1992; 19(2):47-48.

Oliveira ML, Bastos FI, Telles PR, Yoshida CF, Schatzmayr HG, Paetzold U, Pauli G, Schreier E. *Prevalence and risk factors for HBV, HCV and HDV infections among injecting drug users from Rio de Janeiro, Brazil*. Brazilian Journal of Medical & Biological Research 1999; 32(9):1107-1114.

Osmond DH, Padian NS, Sheppard HW, Glass S, Shiboski SC, Reingold A. *Risk factors for hepatitis C virus seropositivity in heterosexual couples*. JAMA 1993; 269(3):361-365.

Osztrogonacz H, Gerevich J, Horvath G, Tolvaj G, David K. *Prevalence of chronic viral hepatitis in drug abusers*. [Hungarian]. Orvosi Hetilap 2000; 141(14):715-718.

Pal SC, Sarkar S, Naik TN, et al. *Explosive Epidemic of HIV Infection in North Eastern States of India, Manipur and Nagaland*. CARC Calling. 1990; 3(3): 2-6.

Panda S, Sarkar S, Mandal BK, et al. *Epidemic of Herpes Zoster Following HIV Epidemic in Manipur, India*. Journal of Infection. 1994; 28: 167-173.

Patti AM, Santi AL, Pompa MG, Giustini C, Vescia N, Mastroeni I, Fara GM. *Viral hepatitis and drugs: a continuing problem*. International Journal of Epidemiology 1993; 22(1):135-139.

Payeras CA, Socias MM, Forteza-Rei BJ, Besalduch VJ. *Hepatitis C viral infection and the consumption of intravenous drugs*. [Spanish]. Revista de Sanidad e Higiene Publica 1992; 66(3-4):233-237.

Peak A, Rana S, Maharjan SH, et al. *Declining Risk for HIV among Injecting Drug Users in Kathmandu, Nepal: The Impact of a Harm-Reduction Programme*. AIDS. 1995; 9(9): 1067-1070.

Piribauer F, Duer W. *Trends in HIV seroprevalence, AIDS and prevention policy among intravenous drug users and men who have sex with men, before and after 1990 in Austria*. European Journal of Epidemiology 1998, 14:635-643.

Pont J, Neuwald C, Salzner G. *Antibody prevalence of parenterally transmitted viruses (HIV-1, HTLV-I, HBV, HCV) in Austrian intravenous drug users*. Infection 1991; 19(6):427-430.

Quaranta JF, Delaney SR, Alleman S, Cassuto JP, Dellamonica P, Allain JP. *Prevalence of antibody to hepatitis C virus (HCV) in HIV-1-infected patients (nice SEROCO cohort)*. Journal of Medical Virology 1994; 42(1):29-32.

Ramsay ME, Balogun MA, Collins M, Balraj V. *Laboratory surveillance of hepatitis C virus infection in England and Wales: 1992 to 1996*. Communicable Disease & Public Health 1998; 1(2):89-94.

Rezza G, Sagliocca L, Zaccarelli M, Nespoli M, Siconolfi M, Baldassarre C. *Incidence rate and risk factors for HCV seroconversion among injecting drug users in an area with low HIV seroprevalence*. Scandinavian Journal of Infectious Diseases 1996; 28(1):27-29.

Ribeiro TT, Brites C, Moreira ED, et al. *Serologic Validation of HIV Infection in a Tropical Area*. Journal of Acquired Immune Deficiency Syndromes. 1993; 6(3): 319-322.

Richardson C, Ancelle-Park R, Papaevangelou G for the European Community Study Group on HIV in Injecting Drug Users. *Factors associated with HIV seropositivity in European injecting users*. AIDS 1993, 7:1485-1491.

Robinson GM, Reynolds JN, Robinson BJ. *Hepatitis C prevalence and needle/syringe sharing behaviours in recent onset injecting drug users*. New Zealand Medical Journal 1995; 108(996):103-105.

Rocha M, Lima M, Tanibata P, et al. *Seroprevalence of the Markers the Hepatitis B Virus and Syphilis in Heterosexual Drug Users*. VIII International Conference on AIDS, Amsterdam, 1992 ; 7:19-24, Abstract PoC 4696.

Rodriguez OES, Gil MLM, Santana JFH, Canal JML, Sanchez AMM. *Prevalence of serologic markers of hbv, hdv, hcv and hiv in noninjection drug users compared to injection drug users in Gran Canaria, Spain*. European Journal of Epidemiology 1998; 14(6):555-561.

Rollag H, Thorvaldsen J, Kittelsen P, Bjoro K, Froland S. *Hepatitis C virus infections among persons attending special clinics dealing with problems related to social conditions*. [Norwegian]. Tidsskrift for Den Norske Laegeforening 1993; 113(19):2397-2400.

Sarkar S, Das N, Panda S, et al. *Rapid Spread of HIV among Injecting Drug Users in North-Eastern States of India*. Bulletin on Narcotics. 1993; XLV(1): 91-105.

Sarkar S, Panda S, Sarkar K, et al. *A Cross-Sectional Study on Factors Including HIV Testing and Counselling Determining Unsafe Injecting Practices among...* Indian Journal of Public Health. 1995; 39(3): 86-92.

Saha MK, Chakrabarti S, Panda S, Naik TN, Manna B, Chatterjee A, Detels R, Bhattacharya SK. *Prevalence of HCV & HBV infection amongst HIV seropositive intravenous drug users & their non-injecting wives in Manipur, India*. Indian Journal of Medical Research 2000; 111:37-39.

San Francisco Department of Health. *HIV/AIDS Epidemiology annual report 2000*. HIV/AIDS seroepidemiology and AIDS Surveillance Section.

Schmitt C, Bertel J, Jacob C. *Incidence of serological markers of hepatitis B and C viruses and HIV in a population of drug abusers hospitalized from 1990 to 1992*. [French]. Annales de Medecine Interne 1994; 145(1):7-12.

Selvey LA, Denton M, Plant AJ. *Incidence and prevalence of hepatitis c among clients of a Brisbane methadone clinic - factors influencing hepatitis c serostatus*. Australian & New Zealand Journal of Public Health 1997; 21(1):102-104.

Shah NG, Celentano DD, Vlahov D, Stambolis V, Johnson L, Nelson KE, Strathdee SA. *Correlates of enrollment in methadone maintenance treatment programs differ by HIV-serostatus*. AIDS 2000, 14:2035-2043.

Shirin T, Ahmed T, Iqbal A, Islam M, Islam MN. *Prevalence and risk factors of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus infections among drug addicts in Bangladesh.* Journal of Health, Population & Nutrition 2000; 18(3):145-150.

Shrestha SM, Shrestha S, Tsuda F, Sawada N, Tanaka T, Okamoto H, Miyakawa Y, Mayumi M. *Infection with GB virus C and hepatitis C virus in drug addicts, patients on maintenance hemodialysis, or with chronic liver disease in Nepal.* Journal of Medical Virology 1997; 53(2):157-161.

Singh S, Crofts N. *HIV Infection among Injecting Drug Users in North-East Malaysia.* AIDS Care. 1993; 5(3): 273-281.

Sinniah M, Ooi BG. *Hepatitis C - the Malaysian story.* Singapore Medical Journal 1993; 34(2):132-134.

Smiatacz T, Wlasiuk M, Paszkiewicz J, Zielinska W. *HBV, HCV and HIV infections among drug addicts-residents of rehabilitation and social adjustment centers in the Gdańsk district.* [Polish]. Przegląd Epidemiologiczny 1991; 45(4):351-355.

Smyth BP, Keenan E, O'Connor JJ. *Bloodborne viral infection in Irish injecting drug users.* Addiction 1998; 93(11):1649-1656.

Smyth BP, Keenan E, O'Connor JJ. *Evaluation of the impact of Dublin's expanded harm reduction programme on prevalence of hepatitis C among short-term injecting drug users.* Journal of Epidemiology & Community Health 1999; 53 (7):434-435.

Smyth R, Keenan E, Dorman A, O'Connor J. *Hepatitis C infection among injecting drug users attending the National Drug Treatment Centre.* Irish Journal of Medical Science 1995; 164(4):267-268.

Somainsi B, Wang J, Perozo M, Kuhn F, Meili D, Grob P, Flepp M. *A continuing concern: HIV and hepatitis testing and prevalence among drug users in substitution programmes in Zurich, Switzerland.* AIDS Care 2000; 12(4):449-460.

Spencer JD, Latt N, Beeby PJ, Collins E, Saunders JB, McCaughan GW, Cossart YE. *Transmission of hepatitis C virus to infants of human immunodeficiency virus-negative intravenous drug-using mothers: rate of infection and assessment of risk factors for transmission.* Journal of Viral Hepatitis 1997; 4(6):395-409.

Stark K, Schreier E, Muller R, Wirth D, Driesel G, Bienzle U. *Prevalence and determinants of anti-HCV seropositivity and of HCV genotype among intravenous drug users in Berlin.* Scandinavian Journal of Infectious Diseases 1995; 27(4):331-337.

Stark K, Muller R, Bienzle U, Guggenmoos-Holzmann I. *Frontloading: a risk factor for HIV and hepatitis C virus infection among injecting drug users in Berlin.* AIDS 1996; 10(3):311-317.

Stark K, Bienzle U, Vonk R, Guggenmoos-Holzmann I. *History of syringe sharing in prison and risk of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus infection among injecting drug users in Berlin.* International Journal of Epidemiology 1997; 26(6):1359-1366.

Steffen T, Christen S, Blattler R, Gutzwiller F. *Infectious diseases and public health: Risk-taking behavior during participation in the Swiss program for a medical prescription of narcotics (PROVE).* Substance Use & Misuse 2001; 36(1-2):71-89.

Stein MD, Maksad J, Clarke J. *Hepatitis C disease among injection drug users: knowledge, perceived risk and willingness to receive treatment.* Drug & Alcohol Dependence 2001; 61(3):211-215.

Strathdee SA, Patrick DM, Currie SL, Cornelisse PGA, Rekart ML, Montaner JSG, Schechter MT, Oshaughnessy MV. *Needle exchange is not enough - lessons from the Vancouver injecting drug use study.* AIDS 1997; 11(8):F.

Subhachaturas W, Desjarcais D, Chooranya K, et al. *New Injectors in the HIV Epidemic among Injecting Drug Users in Bangkok, Thailand*. 5th International Congress on AIDS in Asia and the Pacific, Kuala Lumpur, Malaysia. 1999; 10/20-27, Abstract PTCD061.

Suganuma N, Ikeda S, Taketa K, Wang DH, Yamamoto H, Phornphukutkul K, Peerakome S, Sitvacharanum K, Jittiwutikarn J. *Risk analysis of the exposure to GB virus C/hepatitis G virus among populations of intravenous drug users, commercial sex workers and male outpatients at STD clinic in Chiang Mai, Thailand: a cross-sectional case-control study*. Acta Medica Okayama 1998; 52(3):161-167.

Telles PR, Bastos FI, Guydish J, et al. *Risk Behavior and HIV Seroprevalence among Injecting Drug Users in Rio de Janeiro, Brazil*. AIDS. 1997; 11(Suppl. 1): S35-S42.

Thiede H, Hagan H, Murrill CS. *Methadone treatment and HIV and hepatitis B and C risk reduction among injectors in the Seattle area*. Journal of Urban Health 2000; 77(3):331-345.

Thio CL, Nolt KR, Astemborski J, Vlahov D, Nelson KE, Thomas DL. *Screening for hepatitis C virus in human immunodeficiency virus-infected individuals*. Journal of Clinical Microbiology 2000; 38(2):575-577.

Thomas G. *AIDS in India: A Country-wide Threat*. AIDS in India, Rawat Publications, New Delhi. 1994; 151-168.

Thomson JA, Rodger AJ, Thompson SC, Jolley D, Byrne A, Best SJ, Crofts N. *The prevalence of hepatitis C in patients admitted with acute hepatitis to Fairfield Infectious Diseases Hospital, 1971-1975*. Medical Journal of Australia 1998; 169(7):360-363.

Thongcharoen P, Wasi C, Louisirotchanakul S, et al. *Human Immunodeficiency Virus Infection in Thailand*, Mahidol University, Bangkok. 1989; ISBN 974-586-526-5.

Thorpe LE, Ouellet LJ, Levy JR, Williams IT, Monterroso ER. *Hepatitis C virus infection: prevalence, risk factors, and prevention opportunities among young injection drug users in Chicago, 1997-1999*. Journal of Infectious Diseases 2000; 182(6):1588-1594.

Tor J, Llibre JM, Carbonell M, Muga R, Ribera A, Soriano V, Clotet B, Sabria M, Foz M. *Sexual transmission of hepatitis C virus and its relation with hepatitis B virus and HIV*. BMJ 1990; 301(6761):1130-1133.

Trisler Z, Seme K, Poljak M, Celan-Lucu B, Sakoman S. *Prevalence of hepatitis C and G virus infections among intravenous drug users in Slovenia and Croatia*. Scandinavian Journal of Infectious Diseases 1999; 31(1):33-35.

Trmal J, Kelleroval J, Koblizkova R, Krpalkova H, Holasova J. *Effect of needle and syringe exchange programs on the spread of viral hepatitis C*. [Czech]. Epidemiologie, Mikrobiologie, Imunologie 1999; 48(4):171-178.

Trubner K, Polywka S, Puschel K, Laufs R. *Hepatitis C in deceased drug addicts*. International Journal of Legal Medicine 1991; 104(5):251-254.

Ungchusak K, Sriprapandh S, Pinichapongsa S, et al. *First National Sentinel Seroprevalence Survey of HIV-1 Infection in Thailand: June 1989*. Thai AIDS Journal. 1989; 1(2): 57-74.

Unlinked Anonymous HIV surveys steering group. *Prevalence of HIV in the United Kingdom, Data to end 1998*. London. Department of Health, Public Health Laboratory Service, Institute of Child Health (London). Annual report of the unlinked anonymous prevalence monitoring programme. 1998 Prevalence of HIV in the United Kingdom.

Utsumi T, Hashimoto E, Okumura Y, Takayanagi M, Nishikawa H, Kigawa M, Kumakura N, Toyokawa H. *Heterosexual activity as a risk factor for the transmission of hepatitis C virus*. Journal of Medical Virology 1995; 46(2):122-125.

Vanbeek I, Buckley R, Stewart M, MacDonald M, Kaldor J. *Risk factors for hepatitis c virus infection among injecting drug users in Sydney*. Genitourinary Medicine 1994; 70(5):321-324.

Vanbeek I, Dwyer R, Dore GJ, Luo KH, Kaldor JM. *Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting - retrospective cohort study*. BMJ 1998; 317(7156):433-437.

Vanderschueren S, Van Renterghem L, Plum J, Verhofstede C, Mak R, Vincke J. *Hepatitis C among risk groups for HIV and hepatitis B*. International Journal of STD & AIDS 1991; 2(3):185-187.

Vanichseni S, Wright N, Akarasewi P, et al. *Case Control Study of HIV Positivity among Male Intravenous Drug Addicts (IVDA) in Bangkok*. V International Conference on AIDS, Montreal. 1989; 6/4-9, Poster W.G.P. 19.

Vanichseni S, Sakuntanaga P, et al. *Results of Three Seroprevalence Survey for HIV in IVDU in Bangkok*. VI International Conference on AIDS, San Francisco. 1990; 6/20-24, Session F.C.105.

Vanichseni S, Choopanya K, Friedmann P, et al. *Estimated HIV Incidence among Injecting Drug Users in Bangkok Implication for a Vaccine Trial*. 3rd International Conference on AIDS in Asia and the Pacific, Chiang Mai, Thailand. 1995; 9/17-21, Poster PA813.

Vanichseni S, Kitayaporn D, Mastro TD, Mock PA, Raktham S, Des J, Sujarita S, Srisuwanvilai LO, Young NL, Wasi C, Subbarao S, Heyward WL, Esparza L, Choopanya K. *Continued high HIV-1 incidence in a vaccine trial preparatory cohort of injection drug users in Bangkok, Thailand*. AIDS 2001; 15(3):397-405.

Verbaan H, Andersson K, Eriksson S. *Intravenous drug abuse--the major route of hepatitis C virus transmission among alcohol-dependent individuals?* Scandinavian Journal of Gastroenterology 1993; 28(8):714-718.

Villano SA, Vlahov D, Nelson KE, Lyles CM, Cohn S, Thomas DL. *Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland*. Journal of Clinical Microbiology 1997; 35(12):3274-3277.

Vlahov D, Munoz A, Anthony JC, Cohn S, Celentano DD, Nelson KE. *Association of drug injection patterns with antibody to human immunodeficiency virus type 1 among intravenous drug users in Baltimore, Maryland*. American Journal of Epidemiology 1990, 132:5:847-856.

Vlahov D, Anthony JC, Munoz A, Margolick J, Nelson KE, Celentano DD, Solomon L, Polk BF. *The alive study: A longitudinal study of HIV-1 infection in intravenous drug users: description and methods*. Journal of Drug Issues 1991; 21(4), 759-776.

Wada K, Greberman SB, Konuma K, Hirai S. *HIV and HCV infection among drug users in Japan*. Addiction 1999; 94(7):1063-1069.

Waddell RG. *Hepatitis C and the history of injecting drug use in South Australia*. [letter; comment]. Medical Journal of Australia 1994; 161(4):286.

Weinstock HS, Bolan G, Reingold AL, Polish LB. *Hepatitis C virus infection among patients attending a clinic for sexually transmitted diseases*. JAMA 1993; 269(3):392-394.

Weniger BG, Limpakarnjanarat K, Ungchusak K, et al. *The Epidemiology of HIV Infection and AIDS in Thailand*. AIDS. 1991; 5 (suppl 2): S71-S85.

Westh H, Worm AM, Jensen BL, Kroon S, Kvinesdal B, Nielsen CM, Wantzin P. *Hepatitis C virus antibodies in homosexual men and intravenous drug users in Denmark*. Infection 1993; 21(2):115-117.

Widell A, Hansson BG, Berntorp E, Moestrup T, Johansson HP, Hansson H, Nordenfelt E. *Antibody to a hepatitis C virus related protein among patients at high risk for hepatitis B*. Scandinavian Journal of Infectious Diseases 1991; 23(1):19-24.

Wiebel WW, Jimenez A, Johnson W, Ouellet L, Jovanovic B, Lampinen T, Murray J, O'Brien MU. *Risk behaviour and HIV seroincidence among out-of-treatment injection drug users: a four-year prospective study*. Journal of acquired immune deficiency syndromes and Human Retrovirology 1996, 12:282-289.

Will T. *Early decline in an epidemic: evolution of the prevalences of HIV, hepatitis B, hepatitis C and aminotransferases in intravenous drug abusers in Strasbourg between 1980 and 1990*. [French]. Revue Medicale de la Suisse Romande 1999; 119(4):329-334.

Woodfield DG, Harness M, Rix-Trott K, Tsuda F, Okamoto H, Mayumi M. *Identification and genotyping of hepatitis C virus in injectable and oral drug users in New Zealand*. Australian & New Zealand Journal of Medicine 1994; 24(1):47-50.

Wolk J, Wodak A, Morlet A, Guinan JJ, Gold J). *HIV-related risk-taking behaviour, knowledge and serostatus of intravenous drug users in Sydney*. Med J Aust, 1990, 152: 453-458.

World Health Organisation Programme on Substance Abuse Collaborative Study Group (WHO PSA)). *Multi-City Study on Drug Injecting and Risk of Infection*. WHO/PSA. 1994, 94.4, Geneva.

Worm AM, Gottschau. *No change in incidence and prevalence of HIV among intravenous drug users in Copenhagen from 1985 to 1990*. Journal of acquired immune deficiency Syndromes, 1993; 6:845-848.

Wormser GP, Forseter G, Joline C, Tupper B, O'Brien TA. *Hepatitis C in HIV-infected intravenous drug users and homosexual men in suburban New York City*. JAMA 1991; 265(22):2958.

Wright NH, Vanichseni S, Akarasewi P, et al. *Was the 1988 HIV Epidemic among Bangkok's Injecting Drug Users a Common Source Outbreak?* AIDS. 1994; 8(4): 529-532.

Xinhua S, Junhua N, Qili G. *The Growing Problem of AIDS in Asia*. VI International Conference on AIDS, San Francisco, 1990; 6/24, Closing Ceremony, vol. 3, p. 93.

Ye S. *Prevalence of antibody to hepatitis C virus in 177 drug addicts*. [Chinese]. Chung-Hua Liu Hsing Ping Hsueh Tsa Chih Chinese Journal of Epidemiology 1993; 14(1):45-48.

Zeldis JB, Jain S, Kuramoto IK, Richards C, Sazama K, Samuels S, Holland PV, Flynn N. *Seroepidemiology of viral infections among intravenous drug users in northern California*. Western Journal of Medicine 1992; 156(1):30-35.

OTHER REFERENCES

ABS (Australia Bureau of Statistics)(1995). Deaths, Australia 1994. ABS Catalogue No. 3302.0. AGPS, Canberra, 1995.

Alcibes P, Munoz A, Vlahov D and Freidlan GH (1993). *Incubation period of human immunodeficiency virus*. Epidemiol Rev, 15: 303-318

Becker NG, Watson LF and Carlin JB (1991). *A method of non-parametric back-projection and its application to AIDS data*. Stat Med, 10: 1527-1542

Bennett WG, Inoue Y, Beck JR, et al (1997). *Estimates of the cost-effectiveness of a single course of interferon-alpha2B in patients with histologically mild chronic hepatitis C*. Ann Intern Med, 127: 855-865.

Bonkovsky HL, Woolley JM and the Consensus Interferon Study Group (1999). *Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy*. Hepatology, 29: 264-270.

Bruneau J, Lamothe F, Franco E, et al (1997). *High rates of HIV infection among injecting drug users participating in needle exchange programs in Montreal: results of a cohort study*. Am J Epidemiol, 145: 994-1002.

Des Jarlais DC, Hagan H, Friedman S, et al (1995). *Maintaining low HIV seroprevalence in populations of injecting drug users*. JAMA, 274: 1226-1231.

Drucker E, Lurie P, Wodak A and Alcabes P (1998). *Measuring harm reduction: the effects of needle and syringe exchange programs and methadone maintenance on the ecology of HIV*. AIDS, 12 (Suppl A): S217-S230.

Drummond et al (1997). *Methods for the Economic Evaluation of Health Care Programmes*; 2nd edition, Oxford University Press

English D, Holman CDJ, Milne E, et al (1995). *The quantification of drug caused morbidity and mortality in Australia, 1995 edition*. Commonwealth Department of Human Services and Health, Canberra, 1995.

Fattovich G, Giustina G, Degos F, et al (1997). *Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients*. Gastroenterol, 112: 463-472.

Freeman A, Dore GJ, Law MG, Thorpe M, Von Overbeck J, Lloyd A, Marinos G and Kaldor JM (2001). *Estimating progression to cirrhosis in chronic hepatitis C*. Hepatology, 34: 809-816.

Gulich AE, Wan X, Law MG, Coates M and Kaldor JM (1999). *Risk of cancer in people with AIDS*. AIDS, 13: 839-843.

Guydish J, Bucardo J, Young M, Woods W, Grinstead O and Clark W (1993). *Evaluating needle exchange: Are there negative effects?* AIDS, 7: 871-876.

Hagan H, McGough JP, Thiede H, et al (1999). *Syringe exchange and risk of infection with hepatitis B and C viruses*. Am J Epidemiol, 149: 203-213.

Hall WD, Ross JE, Lynskey MT, Law MG and Degenhardt LJ (2000). *How many dependent heroin users are there in Australia?* Med J Aust, 173: 528-531.

Holtgrave DR and Pinkerton SD (1997). *Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs*. JAIDS, 16: 54-62.

Hurley SF, Jolley DJ and Kaldor JM (1997). *Effectiveness of needle-exchange programmes for prevention of HIV infection*. Lancet, 349: 1797-1800.

Hurley SF, Kaldor JM, Carlin JB, et al (1995). *The usage and costs of health services for HIV infection in Australia*. AIDS, 9: 777-785.

Law MG on behalf of the Hepatitis C Virus Projections Working Group (1999). *Modelling the hepatitis C virus epidemic in Australia*. J Gastro Hepatol, 14:1100-1107.

MacDonald M, Crofts N and Kaldor J (1996). *Transmission of hepatitis C: Rates, routes and cofactors*. Epidemiol Rev, 18: 137-148.

Marschner IC and Watson LF (1992). *An improved EMS algorithm for back-projection of AIDS incidence data*. Research Report 92/1, Department of Statistics, La Trobe University, Melbourne.

NCHECR (2001). *HIV/AIDS, viral hepatitis and sexually transmissible infections in Australia Annual Surveillance Report 2001*. National Centre in HIV Epidemiology and Clinical Research (Ed), Sydney, 2001.

Rodger AJ, Jolley D, Thompson SC, Lanigan A and Crofts N (1999). *The impact of diagnosis of hepatitis C virus on quality of life*. *Hepatology*, 30: 1299-1301.

Rosenberg PS, Gail MH and Carroll RJ (1992). *Estimating HIV prevalence and projecting AIDS incidence in the United States: a model that accounts for therapy and changes in the surveillance definition of AIDS*. *Stat Med*, 11: 1633-1655.

Schoenbaum EE, Hartel DM and Gourevitch MN (1996). *Needle exchange use among a cohort of injecting drug users*. *AIDS*, 10: 1729-1734.

Shiell A, Briggs A and Farrell G (1994). *The cost effectiveness of alpha interferon in the treatment of chronic active hepatitis C*. *Med J Aust*, 160: 268-272.

Tengs, Tammy O, Wallace, Amy, *One Thousand Health-Related Quality-of-Life Estimates*, *Medical Care*, 2000; Vol 38 No. 6: 583-637

Thorley A (1981). *Longitudinal studies of drug dependence*. In: *Drug problems in Britain: a review of ten years*. Eds: Edwards G, Busch C. Academic Press.

US Census Bureau & UNAIDS (2000). *HIV/AIDS Surveillance Data Base*. Health Studies Branch, International Programs Center Population Division, US Census Bureau, Washington.

van Ameijden EJC, van den Hoek JAR and Coutinho RA (1994). *Injecting risk behaviour among drug users in Amsterdam 1986 to 1992, and its relationship to AIDS prevention programs*. *Am J Pub Health*, 84: 275.

Watters JK, Estilo MJ, Clark GL and Lorvick J (1994). *Syringe and needle exchange as HIV/AIDS prevention for injecting drug users*. *Journal of American Medical Association*, 271: 115-120.

Wolk J, Wodak A, Guinan JJ, Macaskill P and Simpson JM (1990). *The effect of a needle and syringe exchange on a methadone maintenance unit*. *British Journal of Addiction*, 85. 1445-1450.